Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$58.85 USD
+0.06 (0.10%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $58.81 -0.04 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
EXAS 58.85 +0.06(0.10%)
Will EXAS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EXAS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for EXAS
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
EXAS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
Other News for EXAS
Exact Sciences Announces Board Member Retirement
Artisan Mid Cap Fund Q1 2024 Commentary
Baron Health Care Fund Q1 2024 Shareholder Letter
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update
Exact Sciences CFO's resume 'impressive,' says William Blair